Trial Profile
The Efficacy of Botulinum Toxin Type a in Treating Peyronie's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Peyronie's disease
- Focus Therapeutic Use
- 03 Feb 2020 Status changed from recruiting to completed.
- 07 Nov 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 07 Nov 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.